Review decision – September 2018

Decision to move the existing guidance to the static list

We would like to update you on the decision made regarding the review of the existing guidance on TA350; Secukinumab for treating moderate to severe plaque psoriasis.

No new evidence is available that would require an update of this guidance. 

NICE’s Guidance Executive has decided to proceed with this proposal without consultation. 

Consequently TA350 will move to the ‘static list’ of technology appraisals.

Review decision paper

Matrix of stakeholders

This page was last updated: